XIth Eurasian Hematology-Oncology Congress - EHOC 2020

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
A

miRNAs in MM: Dysregulated miRNA Expression Cancer Cells, miR-221/222 Cluster in More Favorable Prognosis, miR-15a & miR-16 in Bone Disease

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Aristea-Maria Papanota
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Aristea-Maria Papanota
0 views
January 12, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Myeloma
15:54
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MRD in Newly Diagnosed MM: MRI vs. PET/CT, RVD+/-ASCT, Dara+Len to R…

Feat. E. Terpos
14:53
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

miRNAs in MM: Dysregulated miRNA Expression Cancer Cells, miR-221/22…

Feat. A. Papanota
23:52
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Decision Making in R/R MM: What Options to Consider for 1st Relapse …

Feat. A. Maiolino
16:34
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Frontline MM Updates: What Are the Benefits of Long-Term, Continuous…

Feat. M. Mateos